Food and Drug Regulations
Marginal note:Sale to institution
J.01.059 (1) Despite section C.08.002 and subject to subsections (3) and (4), a licensed dealer may sell a restricted drug to an institution for one of the following purposes if the institution submits to the dealer or the Minister an application to purchase the drug and the Minister issues a prior written authorization for the sale:
(a) clinical testing in the institution by qualified investigators for the purpose of determining the hazards and efficacy of the drug; or
(b) laboratory research in the institution by qualified investigators.
Marginal note:Content of application
(2) The application must contain the following information:
(a) the name and the municipal address of the institution;
(b) the names and qualifications of the qualified investigators;
(c) the name, form, quantity and strength per unit of the restricted drug being requested;
(d) details of the proposed use of the drug; and
(e) the name and municipal address of the licensed dealer from whom the institution proposes to purchase the drug.
Marginal note:Application to licensed dealer
(3) If the institution submits the application to the licensed dealer, the dealer must provide a copy of it to the Minister.
Marginal note:Authorization by Minister
(4) After reviewing the application received from the institution or the copy of it received from the licensed dealer, the Minister may, subject to any terms and conditions that the Minister has reasonable grounds to believe are necessary, authorize in writing
(a) the sale by the licensed dealer to the institution of the restricted drug applied for in the form, quantity and strength per unit specified by the Minister; and
(b) the possession of the restricted drug by qualified investigators for clinical testing of the drug in the institution for the purpose of determining its hazards and efficacy or to conduct laboratory research with the drug in the institution.
Marginal note:Authorized use only
(5) The institution must use the restricted drug only in accordance with the written authorization.
- SOR/2019-171, s. 22
Page Details
- Date modified: